Alpine immune sciences, inc. (ALPN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Net Income (Loss) Attributable to Parent

-35,004

-41,852

-46,847

-47,511

-43,562

-36,487

-29,670

-15,409

-11,100

-7,783

0

0

0

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense

298

468

453

447

613

388

355

310

275

241

130

104

85

69

0

0

0

-

0

0

0

Amortization of premium/discount on investments

269

360

490

486

801

669

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

149

140

137

148

160

169

175

175

131

87

0

0

0

-

-

-

-

-

-

-

-

Deferred income tax

-

-

-

-

-

-305

-509

-509

-256

-204

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

3,273

3,041

2,992

2,711

2,552

2,309

1,888

1,573

1,297

838

-1,654

-1,031

-578

77

2,884

2,380

1,899

1,343

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

1,334

408

4,636

-187

-396

-66

0

0

0

-

-

-

-

26

-346

-91

2,402

-198

0

0

0

Right-of-use asset

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-3,295

816

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

202

-

986

-693

77

80

-540

762

-1,442

65

0

0

0

Deferred revenue

344

1,435

2,068

2,107

-241

-480

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities

305

-195

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

-

-

-461

-

0

0

0

-

-

-

-

-

-

-

-

Increase (Decrease) In Deferred Rent And Other Operating Liabilities

-

-

-

-

-

-

-

-

-7

-

0

0

0

-

-

-

-

-

-

-

-

Accrued direct program expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,380

1,060

1,453

311

0

0

0

Accrued employee benefits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

8

197

1,465

0

0

0

Accrued other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

Net cash used in operating activities

-33,817

-35,346

-39,073

-35,870

-35,208

-28,416

-24,855

-22,169

-18,839

-16,572

0

0

0

-

-

-

-

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-21,323

-19,207

0

0

0

Purchases of property and equipment

756

821

344

417

498

495

563

643

596

586

1,201

929

859

782

136

175

167

188

0

0

0

Purchase of short-term investments

51,000

59,382

63,961

71,277

49,122

72,863

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of short-term investments

0

1,391

1,391

1,391

-39,634

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

45,855

-

0

0

0

-

-

-

-

Proceeds from the sale of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from sales and maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net cash provided by investing activities

10,794

16,763

21,511

26,422

47,347

32,118

24,837

-22,374

-25,825

-29,803

0

0

0

-

-

-

-

-

-

-

-

Financing activities
Proceeds from borrowings, net of issuance costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Issuance of Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

37,666

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and common stock warrants

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-64,346

-62,448

0

0

0

Proceeds from sale of common stock, net of offering costs

-20

23,598

23,598

23,598

23,618

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of debt

833

1,333

1,833

2,000

1,500

1,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

9

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

6,137

24,255

23,755

21,611

22,120

-991

-491

17,008

38,674

42,688

0

0

0

-

-

-

-

-

-

-

-

Effect of exchange rate on cash, cash equivalents and restricted cash

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents and restricted cash

-16,991

5,666

6,176

12,153

34,245

2,711

-509

-27,535

-5,990

-3,687

0

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-41,387

-85,105

-6,835

-2,821

0

0

0

Supplemental Information
Discount in connection with issuance of debt

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

208

170

135

144

150

149

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Recognition of right-of-use asset

10,290

11,173

11,667

11,757

883

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-